Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
123.06
-2.83 (-2.25%)
Streaming Delayed Price
Updated: 1:23 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
87
88
Next >
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
April 06, 2023
Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years.
Via
The Motley Fool
GILD - Chart Of The Week
April 05, 2023
The daily chart looks pretty strong right now. The stock is trying to break through the resistance line that started around the beginning of December.
Via
Talk Markets
AstraZeneca' Cancer Drug Combo Meets Goal In Late-Stage Ovarian Cancer Study
April 05, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years
April 04, 2023
Via
Benzinga
2 Ultra-Cheap Dividend Stocks to Buy in April
April 04, 2023
These two big pharma stocks are trading at steep discounts.
Via
The Motley Fool
Russia Warns As Finland Joins NATO, Spotify Highlights Struggle With Live Audio, Anticompetitive Charges Against Activision Blizzard: Today's Top Stories
April 04, 2023
Benzinga Finland Joins NATO Doubling Border Length, Russia Issues Warning
Via
Benzinga
Merck & Co Unusual Options Activity For March 29
March 29, 2023
Via
Benzinga
Merck Releases Keytruda Data In Frontline Endometrial Cancer Patients
March 28, 2023
Via
Benzinga
3 Top Healthcare Stocks to Buy for April
April 04, 2023
These pharmaceutical companies' shares are down, but their prospects are rising.
Via
The Motley Fool
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
April 04, 2023
Via
Benzinga
After Denying Earlier, Pfizer & Merck Marginally Cut Prices For COVID-19 Treatments In China
April 04, 2023
Pfizer Inc (NYSE: PFE) and Merck & Co Inc (NYSE: MRK) have reportedly lowered the prices of their respective COVID-19 treatments in China.
Via
Benzinga
US Court Favors Bayer In Lawsuit Against Merck On Talc Liabilities
April 04, 2023
Via
Benzinga
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
April 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
Is the Best-Performing Dow Stock of the Past Year a Buy?
March 21, 2023
This company defied the bear market with impunity.
Via
The Motley Fool
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
April 03, 2023
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners.
Via
Talk Markets
OncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting Study
April 03, 2023
OncoSec Medical Incorporated (NASDAQ: ONCS) shares plummeted Monday following Phase 2 KEYNOTE-695 clinical trial data. The primary endpoint of the overall response rate (ORR) was not met.
Via
Benzinga
Twitter's Revenue Drops As Advertisers Voice Major Concerns
April 01, 2023
Twitter has been bleeding advertisers since Elon Musk took over, with several high-profile companies pausing promotions on the platform.
Via
Benzinga
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
March 31, 2023
Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many...
Via
Benzinga
11 Stocks: 9 Dividend Payers 2 For Growth
March 30, 2023
Not all stocks are the same, and not all stocks serve the investor’s needs.
Via
Talk Markets
Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
March 30, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
March 29, 2023
From
Merck & Co., Inc.
Via
Business Wire
Moderna's CEO Just Gave Investors a Huge Reason to Sell the Stock
March 29, 2023
The stock looks overpriced, and that's without taking into account all the risks.
Via
The Motley Fool
Don't Be Fooled by These 3 Value Traps
March 28, 2023
Approximately one out of every ten U.S. listed stocks have a positive P/E ratio less than 10. Some are justifiably cheap; others are merely fool’s gold.
Via
MarketBeat
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status
March 27, 2023
From
Merck & Co., Inc.
Via
Business Wire
BioNTech Is Ripe For A Rebound In 2023
March 27, 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
3 Simple Ways to Supercharge Your Biopharma Investing Using Artificial Intelligence
March 24, 2023
Your stock screening and research process will never be the same.
Via
The Motley Fool
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
March 23, 2023
Via
Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
March 21, 2023
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.
Via
InvestorPlace
7 Defensive Stocks to Buy During This Chaotic Spell
March 20, 2023
With turmoil erupting on Wall Street over the banking sector crisis, investors should turn to reliable defensive stocks to buy.
Via
InvestorPlace
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
March 20, 2023
With the COVID pandemic still ongoing, having claimed more than 6.8 million lives from about 758 million cases and crippling the global economy, there are several reasons why drug research and...
Via
Benzinga
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
87
88
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.